Healthcare entity
Coverage clusters in regulation, which accounts for 13 of those 20, with the remainder spread across 5 other categories. Robert F. Kennedy Jr. is the most frequent co-covered peer, appearing in 5 of the 20 tracked stories. Against the same-window beat baseline of 21% negative, this entity's 25% share is more negative.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Coverage clusters in regulation, which accounts for 13 of those 20, with the remainder spread across 5 other categories. Robert F. Kennedy Jr. is the most frequent co-covered peer, appearing in 5 of the 20 tracked stories. Against the same-window beat baseline of 21% negative, this entity's 25% share is more negative. That works out to roughly 3.6 stories per week across a 39-day span. The busiest single day carried 4. Their average consequence score of 6.3 runs above the beat's 5.8 for that window. Source depth averages 2.3 original sources per story, versus 2.4 across the same-window beat baseline. We currently track 20 Healthcare stories that mention FDA, published between July 20, 2026 and August 27, 2026.
Computed from the 20 stories linked to this entity, with beat comparisons drawn from all 380 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FDA. Shared-story counts are live from our verified record — not editorial picks.
Cash runway into first half of 2029
Proceeds from the $150 million private placement are expected to fund a planned NDA submission and operations into the first half of 2029.
CRPS-RISE Phase 3 topline results expected
Ambros expects to report topline results from the pivotal CRPS-RISE trial evaluating neridronate in warm CRPS-1.
Expected FDA submission
Lilly plans to file retatrutide for FDA approval.
PDUFA Date
Target date for FDA decision on INO-3107 accelerated approval.
APOLLO Data Readout
Expected release of Phase 2 data which will support the traditional NDA filing.
Expected Finalization
Anticipated period for final guidance after public comment and review.
Expected Deal Close
The all-stock merger is anticipated to close, pending shareholder and regulatory approvals.
FDA Approval
FDA approves daraxonrasib (Rasonque) for metastatic pancreatic cancer, six months ahead of the regulatory deadline.
Merger and $150M financing announced
Werewolf Therapeutics and Ambros Therapeutics announce a definitive all-stock merger and an oversubscribed $150 million private placement.
News reports on Class 1 recall
iHeartMedia stations report the FDA's highest-risk recall classification, citing 12 CDC-confirmed E. coli cases across two states.
Trump announces Heidi Overton as FDA Commissioner nominee
President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.
FDA final decision deadline
The agency must decide whether to approve the first mRNA-based influenza vaccine, with major implications for the platform’s future.
Merger and Earnings Announcement
Supernus unveils definitive agreement to merge with Indivior and releases Q2 2026 financial results.
Early access program announced
Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.
PCAC Votes to Recommend Six Peptides
The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
Clarification on US Primary Endpoint
Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
FDA PCAC Public Meeting Begins
The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
FDA Briefing Confirms Continued Focus on Taylor Farms
Acting FDA Food Chief Donald Prater stated that traceback and outbreak data still converge on shredded iceberg lettuce from Taylor Farms' central Mexico locations, despite the faulty test. Border testing is underway.
FDA Retracts Test as False Positive
After quality control checks, the FDA determined the rapid test was a false positive and notified Taylor Farms. The agency removed the initial finding from its site.
FDA Posts Positive Rapid Test and Taylor Farms Initiates Recall
The FDA published a rapid test result indicating cyclospora on a Taylor Farms lettuce sample to its website. Taylor Farms announced a voluntary recall of 25 shredded lettuce and salad mix products.
For healthcare providers and health systems, FDA approval of Rasonque introduces the first RAS-targeted oral therapy for metastatic pancreatic cancer, nearly doubling median overall survival from 6.6 to 13.2 months, with implications for treatment protocols, oncologist education, and patient access.
The Werewolf-Ambros merger creates a Nasdaq-listed company focused on neridronate for CRPS-1, an under-served pain indication affecting 65,000 newly diagnosed U.S. patients yearly. A $150 million financing funds a 270-patient pivotal Phase 3 trial with topline data expected in 2028.
Source: rttnews.com · Investing South Africa
Public health and health policy leaders should monitor the FDA's Class 1 recall escalation after 12 E. coli infections in two states were linked to imported frozen blueberries sold at Publix in eight states; no deaths have been reported.
A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts.
For health IT, medical device and telehealth leaders, Overton's nomination signals a period of regulatory uncertainty. Her backing of MAHA and most favored nation drug pricing could reshape digital health evidence standards, diagnostics oversight and vaccine-adjacent software, even as deregulatory forces promise faster approvals. Confirmation will test how the FDA balances innovation with public health safeguards.
Public health officials are responding to 17 active foodborne illness outbreaks—including Cyclospora and Salmonella—by proposing that food companies must notify the FDA of GRAS ingredients. This shift could give epidemiologists critical data to trace outbreaks faster and prevent contamination in imported produce, where foreign inspection gaps leave the food supply vulnerable.
Source: wbaltv.com · wmtw.com
As Kalshi and Polymarket expand prediction markets into clinical trials and FDA approvals, a father’s story reveals the human cost behind the bets. Researchers warn of insider trading and eroded trust in medical research.
Source: iowapublicradio.org · news.prairiepublic.org
FDA approval of Moderna's mRNA flu vaccine, with a 26.6% relative efficacy improvement over standard shots, signals a shift in seasonal flu prevention strategies for healthcare systems treating older adults.
Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.
Source: gdnonline.com · 933thedrive.com
Canon Medical Systems’ Olea Medical partners with Median Technologies to bring eyonis LCS, the first FDA-cleared AI for lung nodule detection and malignancy assessment, to U.S. radiology practices, aiming to reduce indeterminate findings and improve screening efficiency.
Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.
Source: The Motley Fool · Eric Volkman (us)
The FDA’s imminent decision on Moderna’s mRNA flu vaccine carries high stakes for healthcare providers and the vaccine industry. While an advisory panel backed approval, political skepticism from HHS Secretary RFK Jr. and a prior agency reversal add uncertainty. The ruling could either accelerate or stall mRNA’s expansion beyond COVID-19.
A key FDA panel vote could expand legal access to BPC-157, TB-500, and four other peptides through compounding pharmacies. Vanta is positioning its telehealth and pharmacy network to deliver these therapies to consumers seeking longevity care.
An FDA advisory committee voted 8-6 to recommend allowing pharmacy compounding of unapproved peptides like BPC-157, raising urgent questions about patient safety, telehealth marketing practices, and regulatory integrity.
Source: santafenewmexican.com · texarkanagazette.com
For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
A narrow FDA advisory panel vote to ease peptide compounding restrictions could trigger a rapid expansion of telehealth-delivered wellness treatments, despite a stark lack of safety data. With HHS Secretary RFK Jr. supporting access, healthcare providers must prepare for a new era of direct-to-consumer peptide therapies.
A new study shows that a p-tau217 blood test can forecast up to 78% ten-year risk of cognitive decline in healthy older adults, raising urgent questions for healthcare providers, payers, and health IT systems about whether and how to implement predictive testing absent disease-modifying treatments.
Clinicians and public health advocates are sounding the alarm over a potential ban on mail-order mifepristone, which now accounts for 30% of U.S. abortions. Over 400 state lawmakers cite rural hospital closures and transportation barriers as evidence that ending telehealth abortion would create a healthcare crisis for millions.
Source: Alanna Vagianos (us) · Alanna Vagianos (in)
The FDA's investigation into a multistate cyclospora outbreak traced to Taylor Farms lettuce from Mexico continues despite a false positive rapid test. The incident highlights challenges in foodborne pathogen detection and the recall's implications for food safety oversight.
Source: chicagotribune.com · STAT News
The FDA's false positive announcement for a Taylor Farms lettuce sample adds a twist to the thousands of cyclosporiasis cases across 34 states. While the test was wrong, the outbreak raises critical questions about diagnostic accuracy and the speed of public health responses.
Source: wftv.com · Seeking Alpha
FDA is linked from 83 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
